42 related articles for article (PubMed ID: 23271787)
21. Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.
Nguyen TH; Guedj J; Yu J; Levi M; Mentré F
CPT Pharmacometrics Syst Pharmacol; 2013 Jul; 2(7):e56. PubMed ID: 23863865
[TBL] [Abstract][Full Text] [Related]
22. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
J Med Virol; 2013 Jan; 85(1):65-70. PubMed ID: 23154876
[TBL] [Abstract][Full Text] [Related]
23. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
Backus LI; Boothroyd DB; Phillips BR; Belperio P; Halloran J; Mole LA
Clin Gastroenterol Hepatol; 2011 Jun; 9(6):509-516.e1. PubMed ID: 21397729
[TBL] [Abstract][Full Text] [Related]
24. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
25. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.
Cammà C; Cabibbo G; Bronte F; Enea M; Licata A; Attanasio M; Andriulli A; Craxì A
J Hepatol; 2009 Oct; 51(4):675-81. PubMed ID: 19665247
[TBL] [Abstract][Full Text] [Related]
26. Individualization of antiviral treatment regimens for chronic hepatitis C.
Paulon E; Naoumov NV
Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):321-5. PubMed ID: 16538101
[TBL] [Abstract][Full Text] [Related]
27. Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months?
Bizollon T; Trepo C
J Hepatol; 2002 Aug; 37(2):274-6. PubMed ID: 12127435
[No Abstract] [Full Text] [Related]
28. Transmission, natural history, and treatment of hepatitis C virus infection in the pediatric population.
Schwimmer JB; Balistreri WF
Semin Liver Dis; 2000; 20(1):37-46. PubMed ID: 10895430
[TBL] [Abstract][Full Text] [Related]
29. Update on the treatment of patients with non-genotype 1 hepatitis C virus infection.
Mangia A; Mottola L; Piazzolla V
Clin Infect Dis; 2013 May; 56(9):1294-300. PubMed ID: 23271787
[TBL] [Abstract][Full Text] [Related]
30. Individualisation of antiviral therapy for chronic hepatitis C.
Teoh NC; Farrell GC; Chan HL
J Gastroenterol Hepatol; 2010 Jul; 25(7):1206-16. PubMed ID: 20594246
[TBL] [Abstract][Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
